1049 results about "Transfection" patented technology

Recombinant NK cells, and especially recombinant NK-92 cells express a chimeric antigen receptor (CAR) having an intracellular domain of FcεRIγ. Notably, CAR constructs with an intracellular domain of FcεRIγ had a substantially prolonged duration of expression and significantly extended cytotoxicity over time. The CAR may be expressed from RNA and DNA, preferably as a tricistronic construct that further encodes CD16 and a cytokine to confer autocrine growth support. Advantageously, such constructs also enable high levels of transfection and expression of the recombinant proteins and provide a convenient selection marker to facilitate rapid production of recombinant NK / NK-92 cells.

The invention relates to the technical field of cytology, in particular to a grass carp brain astrocyte line and application thereof, the grass carp brain astrocyte line is preserved in China Center for Type Culture Collection on May 7, 2025, and the preservation number of the grass carp brain astrocyte line is CCTCC NO: C2025149. The grass carp brain astroglia cell line provided by the invention has the capability of efficiently proliferating GCRV-II, and the virus titer of the GCRV-II replicated in the cell line at least can reach 1.38 * 10 < 8 > pfu / mL or above; after the GCRV-II is blindly passed for 5 generations in a grass carp astroglia cell line, the grass carp can still have typical bleeding symptoms and death due to the virus. And the exogenous plasmid transfected grass carp brain astroglia cell line has similar transfection efficiency to commercial grass carp kidney cells. Therefore, the invention lays an important foundation for deep research of pathogenic mechanism of GCRV-II, vaccine preparation, antiviral drug screening and prevention and control of grass carp viral hemorrhagic disease.

The invention discloses a self-replicating RNA (Ribonucleic Acid) molecule, a porcine rotavirus RNA vaccine and application thereof, and relates to the technical field of vaccines. According to the present invention, the coding sequence of the porcine rotavirus G9P23 type VP4 protein is optimized, such that the fact that the saRNA prepared by using the nucleotide sequence represented by the SEQ ID NO: 10 can secrete the high porcine rotavirus G9P23 type VP4 protein antigen after the cell transfection is found; after the optimized porcine rotavirus G9P23 type VP4 protein is used for immunizing experimental animals, the level of neutralizing antibodies generated by the animals can be improved, and the challenge protection effect is enhanced. Therefore, the nucleic acid molecule provided by the invention can be used for developing drugs and vaccines for causing protective immune response in experimental animal bodies. Compared with a traditional vaccine, the vaccine provided by the invention has good immunogenicity and safety, and has a good application prospect.

The invention discloses a construction method and application of a gene modified mesenchymal stem cell. The construction method comprises the following steps: constructing a recombinant lentivirus carrying PD-L1 and ICAM1 genes; the recombinant lentivirus carrying the PD-L1 gene and the ICAM1 gene is transfected with mesenchymal stem cells, and the mesenchymal stem cells are screened by puromycin, so that an engineered mesenchymal stem cell strain modified by the PD-L1 gene and the ICAM1 gene is obtained; the mesenchymal stem cells provided by the invention are modified by engineering genes of PD-L1 and ICAM1, and are screened by puromycin to obtain a mesenchymal stem cell strain capable of stably and highly expressing the genes of PD-L1 and ICAM1; after the mesenchymal stem cells highly expressing the PD-L1 and ICAM1 genes are intravenously injected into an autoimmune hepatitis animal model, the autoimmune hepatitis symptom can be remarkably relieved, the liver injury degree can be reduced, the expression of inflammatory factors can be regulated, the inflammatory reaction can be inhibited, and the obvious curative effect can be achieved.

The present invention provides a method and culture medium for promoting adipogenic differentiation of stem cells in vitro, and belongs to the field of stem cell technology. The present invention inhibits the expression of ENST00000566297.1 gene by designing specific siRNA, thereby significantly promoting the adipogenic differentiation of adipose-derived mesenchymal stem cells (ADSCs). The experimental results show that after transfection of siRNA, the intracellular lipid droplet content is significantly increased, and the adipogenic differentiation efficiency is significantly improved. In addition, the present invention also provides an optimized culture medium formula, including transfection culture medium, adipogenic induction liquid A and adipogenic induction liquid B. This culture medium can better support the adipogenic differentiation process of adipose-derived mesenchymal stem cells, thereby providing new strategies and technical support for adipose tissue engineering and regenerative medicine.

The present invention discloses the application of liver cancer cell ferroptosis inducer miR‑11085‑5p in the preparation of liver cancer treatment drugs, and innovative applications in the field of liver cancer treatment, specifically to the application of liver cancer cell ferroptosis inducer miR‑11085‑5p in the preparation of liver cancer treatment drugs. The present invention adopts lentiviral transfection technology to synthesize miR‑11085‑5p in vitro, and introduce it into liver cancer cells, and effectively induce liver cancer cells to undergo ferroptosis by precisely regulating the key signaling pathway of intracellular AMPKα / Nrf2, significantly inhibiting its proliferation activity. Therefore, for the disadvantages of low efficiency, large side effects and easy recurrence and metastasis of existing treatment methods for liver cancer, the miR‑11085‑5p provided by the present invention may become a biological preparation for the treatment of liver cancer, with potential drug development value, and provide a new solution for the treatment of liver cancer.

The invention discloses a verification method for regulating and controlling proliferation and differentiation of bovine adipocytes by gene interference, which comprises the following steps: cutting bovine adipocyte tissues into small blocks, directly pasting the small blocks in a culture dish for culture, and promoting cell growth and proliferation by using nutrition and growth factors of the tissues; a ZNF423 gene is targeted by adopting an siRNA technology, siRNA is transfected into bovine fat cells by utilizing a transfection reagent, and the siRNA is an interference fragment containing si-ZNF423; the method comprises the following steps: respectively extracting total RNA (Ribonucleic Acid) and total protein of bovine adipocytes, and detecting by utilizing qPCR (Quantitative Polymerase Chain Reaction) quantitative analysis, a WB (White Batch) technology, EdU dyeing, flow cytometry detection, oil red O, BODIPY (Boron Dipyrromethene), Nile Red dyeing, TG (Triglyceride) content determination and the like. According to the invention, ZNF423 gene expression is interfered by the interference fragment containing si-ZNF423, and the effect of inhibiting proliferation and differentiation of bovine adipocytes is detected by various methods, so that the effect of the interference fragment in the bovine adipocytes is known conveniently, and regulation and control of proliferation and differentiation of the bovine adipocytes are realized by interfering gene expression by the interference fragment. The beef quality can be improved; the beef cattle breeding can be optimized.

The invention discloses a nano-carrier for gene editing of aquatic animals. The nano-carrier comprises a) TNP nano-particles and b) Cas9 mRNA and sgRNA. The invention also discloses an application of the TNP nano-particle as an mRNA delivery carrier and a gene editing method based on the nano-carrier, according to the method, the TNP nano-particle with good biocompatibility is used for packaging Cas9 mRNA and sgRNA, and an efficient and low-damage gene editing delivery mode is realized. The nano-carrier is delivered into an embryo of an aquatic animal in a non-invasive manner, so that the transfection efficiency and the specificity of gene editing are optimized. In addition, the method can improve the gene editing efficiency and precision and enhance the embryo survival rate, is simple, convenient and safe to operate and wide in applicability, can support customized gene editing, and is beneficial to promoting the application of gene editing in aquatic product germplasm genetic improvement.

The present disclosure belongs to the field of biotechnology, and specifically relates to a method for efficiently infecting human natural killer (NK) cells and other immune cells with a pseudovirus. Specifically, a viral transfection system provided in the present disclosure has an envelope plasmid with a protein having an X—Y—Z structure. The X is an extracellular (ex) structure of a gibbon ape leukemia virus (GALV) envelope glycoprotein, the Y is a transmembrane (TM) structure of the GALV envelope glycoprotein, and the Z is an intracellular segment portion of a murine virus gene.

The present disclosure provides for improved compositions of ionizable lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Anionic phospholipids, including phosphatidyl serine and phosphatidylglycerol are included in the lipid nanoparticles to increase the transfection efficiency in human dendritic cells. The further incorporation of mono-unsaturated alkyl chain analogs in dimethylaminopropyl-di oxolane or heterocyclic ketal ionizable lipids in the formulation demonstrated high levels of transfection in human dendritic cells, compared to other ionizable lipids in the same family, and demonstrated good stability to oxidative damage. Finally, the use of an ammonium salt of phosphatidylserine allows for the efficient production of PS-targeted LNPs.

The invention relates to the technical field of gene engineering. The invention provides a functional sequence shRNA1 (short hairpin ribonucleic acid 1) for silencing a circular RNAh-hsacirc005838, and further provides a lentiviral vector of the functional sequence shRNA1 and a construction method of the lentiviral vector. The invention also provides a lentivirus packaging titer kit containing the lentiviral vector with the functional sequence shRNA1, and also provides an application of the lentiviral vector with the functional sequence shRNA1 or the lentiviral vector with the functional sequence shRNA1 in preparation of a kit for breast cancer diagnosis. According to the invention, an interference target sequence siRNA1 is obtained by aiming at the annular target gene RNA h-hsacirc005838, then the finally obtained functional sequence shRNA1 can directly and efficiently infect cells and silence the annular RNAh-hsacirc005838 sequence, and the transfection effect is stable.

The invention discloses application of arabinogalactan protein family genes PbrAGP16 in promoting growth of pear pollen tubes, and belongs to the technical field of plant genetic engineering. According to the invention, the gene PbrAGP16 is cloned from pollen of Dangshan pears by using a plant gene cloning technology, and the nucleotide sequence of the gene PbrAGP16 is shown as SEQ ID No.1; the amino acid sequence coded by the gene is SEQ ID No.2 in a sequence table. Researches show that PbrAGP16 can promote growth of pear pollen tubes, the change of PbrAGP16 expression is related to the change of the content of cellulose at the top ends of the pollen tubes, and PbrAGP16 also participates in a regulation mechanism of a self-incompatible reaction. The pollen magnetic transfection technology is adopted to research the function of the gene in the pollen tube, and a wide application prospect is provided for improving the pollination efficiency.

The invention discloses application of Osge as a molecular target to preparation of a medicine for preventing and / or treating fatty liver. According to the invention, the key effect of Osge as a therapeutic target in the treatment of fatty liver diseases caused by high fat diet is confirmed for the first time and is verified in a mouse model, and a method of overexpressing Osge through virus transfection proves that lipid deposition in liver tissues can be effectively reduced and liver balloon-like degeneration can be relieved by improving the expression level of Osge in the liver, so that the fatty liver diseases caused by high fat diet can be effectively treated. The accumulation of lipid droplets is reduced. The invention shows that Osge can be used as a new molecular target for preventing and treating fatty liver, and has important clinical application value in the aspect of treating metabolism-related fatty liver diseases.

The invention belongs to the field of biomedical materials, and particularly relates to a PBAE-DOPE-PEG2000 polymer-lipid nanocomposite and a preparation method and application thereof.The preparation method comprises the steps that a dimethyl sulfoxide-ethanol solution formed by mixing DOPE-PEG2000 lipid and PBAE serves as an oil phase, a sodium acetate / acetic acid buffer solution serves as a water phase, and the PBAE-DOPE-PEG2000 polymer-lipid nanocomposite is prepared through a microfluidic synthesis mode; the PBAE-DOPE-PEG2000 polymer-lipid nano composite material is prepared by the steps of carrying out ultrasonic treatment on the PBAE-DOPE-PEG The polymer-lipid nano composite material can efficiently load exogenous genes, the surface performance of the polymer-lipid nano composite material is changed and the stability of nano particles is improved by introducing DOPE-PEG2000 lipid, membrane fusion can be promoted, the risk of lysosome degradation is reduced, the transfection process of the exogenous genes in recipient cells is accelerated, and efficient expression in 293FT cells is realized. The efficient transfection of the polymer-lipid nanocomposite material is expected to show important application prospects in immune cell therapy or tumor cell therapy.

The invention relates to the technical field of analysis and detection, and particularly provides a method for predicting the transfection efficiency of fluorinated lipid nanoparticles by using multi-nuclear magnetic resonance, and the method comprises the following steps: (1) carrying out nuclear magnetic resonance fluorine spectrum detection on fluorinated nanoparticles to obtain a nuclear magnetic fluorine spectrum of a control group; (2) transfecting the fluorinated nanoparticles into a cell or a mouse living body, and performing nuclear magnetic resonance fluorine spectrum detection on the cell or the living body to obtain a nuclear magnetic fluorine spectrum of an experimental group; and (3) calculating the difference value of the target peak areas of the fluorinated lipid in the experimental group and the control group to predict the transfection efficiency of the fluorinated lipid nanoparticles. The method has good performance in the aspects of specificity, repeatability, stability, linear relation and the like, and can provide effective technical support for large-scale screening of nano medicaments of fluorinated lipid nanoparticles.

The invention discloses an experimental method based on depletion-type nk cells as a lung cancer treatment target, and relates to the technical field of bioinformatics. Comprising the following steps: S1, data processing; s2, identification of cell subset characteristic genes and cell type annotation; s3, re-clustering the NK cells; s4, NK cell function annotation; s5, differential gene expression analysis; s6, analyzing the difference of activation and inhibition of receptor expression by the RGS1 + NK cells through single cells; s7, performing quasi-time sequence analysis; s8, carrying out cell culture and siRNA transfection; s9, detecting the expression condition of an NK92mi cell activated receptor after the RGS1 is knocked down; s10, carrying out a lactic dehydrogenase release experiment; s11, measuring the IFN-gamma content of the cell supernatant; and S12, virtual screening of drugs. Through analysis and experimental verification, the key function of RGS1 in NK cell depletion in lung cancer is disclosed, and a new and potential molecular target is provided for lung cancer treatment.

The present disclosure provides for improved compositions of ionizable lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Anionic phospholipids, including phosphatidylserine and phosphatidylglycerol are included in the lipid nanoparticles to increase the transfection efficiency in human dendritic cells. The further incorporation of mono-unsaturated alkyl chain analogs in dimethylaminopropyl-dioxolane or heterocyclic ketal ionizable lipids in the formulation demonstrated high levels of transfection in human dendritic cells, compared to other ionizable lipids in the same family, and demonstrated good stability to oxidative damage. Finally, the use of an ammonium salt of phosphatidylserine allows for the efficient production of PS-targeted LNPs.

The invention discloses an application of a compound in preparation of a product for enhancing the metabolic activity of hematopoietic stem cells and treating metachromatic white matter dystrophy. The compound comprises Azoramide. Azoramide is adopted to treat transfected hematopoietic stem cells, and cell apoptosis, cell necrosis and mitochondrial respiration conditions of the hematopoietic stem cells are obviously improved, so that the hematopoietic stem cells are expected to be applied to enhancement of transfection efficiency and metabolic activity of the hematopoietic stem cells transfected by the ARSA gene and reduction of ROS generation, and the effectiveness of the hematopoietic stem cells in treatment of MLD diseases is enhanced.

The invention discloses application of a pear transcription factor PbrWHY2 gene in promoting growth of pear pollen tubes, and belongs to the technical field of plant genetic engineering. According to the invention, the gene PbrWHY2 is cloned from pollen of Dangshan pears by using a plant gene cloning technology, and the nucleotide sequence of the gene PbrWHY2 is shown as SEQ ID No.1; the amino acid sequence coded by the gene is SEQ ID No.2 in a sequence table. The PbrWHY2 can promote the growth of a pear pollen tube, the change of the expression of the PbrWHY2 is related to the change of ROS level and cellulose content at the top end of the pollen tube, and meanwhile, the PbrWHY2 also participates in a regulation mechanism of a self-incompatible reaction to regulate a downstream gene PbrAGP16 / PbrRALF6 / PbrGIS1 in a targeted manner. The pollen magnetic transfection technology is adopted to research the function of the gene in the pollen tube, and a wide application prospect is provided for improving the pollination efficiency.

Provided in the present invention is a nitrogen-containing heterocycle-branched cationic lipid. The structure thereof is as represented by general formula (1), wherein the definition of each symbol is consistent with that described herein. The nitrogen-containing heterocycle-branched cationic lipid has a nitrogen-containing heterocycle as a branched core, an amino acid or an amino acid derivative as a linker arm, and a saturated or unsaturated hydrocarbon group as a tail chain; and has the advantages of low toxicity, low immunogenicity and high biocompatibility. In the new cationic lipid of the present invention, the electropositivity of the nitrogen on the nitrogen-containing heterocycle is delocalized to the whole ring, so that the cationic lipid shows higher transfection efficiency and lower cytotoxicity. The new cationic lipid of the present invention contains one or more biodegradable groups between the nitrogen-containing heterocycle and the hydrophobic tail, and the presence of the degradable groups enables a lipid nanoparticle (LNP) prepared from the cationic lipid to be timely degraded in the endosome, such that the problem in the prior art whereby LNPs prepared from a non-degradable lipid accumulate in the endosome and acidify the endosomal environment, thereby hindering the endosomal escape of a drug molecule (such as a nucleic acid) and thus the drug delivered into a cell not being able to function is solved.

The invention relates to a design method of a CAR-T cell model targeting human TROP2 and application of the CAR-T cell model in triple negative breast cancer. The method comprises the following steps: obtaining protein sequences of a light chain and a heavy chain by utilizing a sequence of a targeting drug of the human TROP2; comparing the protein sequences of the light chain and the heavy chain with the sequence of the drug protein, and removing the same sequence part to obtain a variable protein sequence; transforming the variable protein sequence into a base sequence to respectively obtain base sequences of a light chain variable region and a heavy chain variable region, and adding a signal peptide and a connecting region to synthesize two base sequences to obtain a human TROP2 antibody sequence fragment; the preparation method comprises the following steps: synthesizing plasmids carrying a human TROP2 antibody sequence fragment by taking an SFG retroviral vector as a skeleton; and enabling the human T cells to express a target gene through transfection. In the embodiment, the nucleic acid sequence of the human TROP2 antibody as shown in SEQ ID NO.1 and SFG are used as carriers, a retrovirus transfection system is used for constructing a TROP2. CAR-T cell model, the functionality of the TROP2. CAR-T cell on the triple negative breast cancer is defined, and a new method is provided for clinical treatment of the triple negative breast cancer.

The invention relates to a kit for detecting the sensitivity of kidney cancer to a targeted drug, which comprises an RNA (Ribonucleic Acid) nucleic acid probe, and the sequence of the RNA nucleic acid probe is shown as SEQ ID NO: 4. The invention also provides a construction method of the specific annular RNA probe. The construction method comprises the following steps: S1, designing and constructing a recombinant plasmid containing a target gene; s2, constructing a tricRNA (Ribonucleic Acid) vector containing a reverse complementary sequence crossing a backspace junction site and a Broccoli sequence, wherein the reverse complementary sequence crossing the backspace junction site and the Broccoli sequence are subjected to reverse complementary sequence crossing the backspace junction site; s3, carrying out vector transfection on the HEK293T cell to express a tricRNA probe, and extracting the tricRNA probe; and S4, constructing a tricAGAP1 Probe-Broccoli probe. The method comprises the following steps of: constructing a tricAGAP1 probe; the invention provides application of a probe in preparation of a cell imaging probe and in preparation of a kit for detecting sensitivity of kidney cancer to a targeted drug. The invention not only provides a new method and technology for guiding the medication of sunitinib for patients with advanced kidney cancer, but also provides a technical example for the development of other circRNA detection technologies.

Novel lipids for delivery of macromolecules, such as nucleic acids, into eukaryotic cells and tissues are provided. The lipids may be used alone, in combination with other lipids, and / or in combination with other transfection enhancing agents to prepare transfection complexes and complexes for in vivo delivery of bioactive agents.

The present disclosure provides methods for genetically engineering T cells, such as CD4+ T cells, for use in cell therapy. In some aspects, the provided methods include one or more steps for incubating the cells under stimulating conditions, introducing a recombinant polypeptide to the cells through transduction or transfection, and cultivating the cells under conditions that promote proliferation and / or expansion. In some aspects, the incubation and / or the cultivation is performed in the presence of recombinant IL-2. In some aspects, the provided methods are an efficient, reliable means to produce genetically engineered T cells with a high degree of success.

The invention provides nano-particles for generating CAR-T in vivo and application of the nano-particles, and belongs to the technical field of medical preparations. The nanoparticles are nanoparticles which are coupled with a CD7 antibody and entrapped with mRNA (messenger Ribonucleic Acid); the mRNA is obtained by transcription of a target gene; the target gene comprises a TROP2 single-chain antibody; the nucleotide sequence of the TROP2 single-chain antibody is as shown in SEQ ID NO: 1. The nucleotide sequence of the TROP2 single-chain antibody is optimized, the CAR containing the TROP2 single-chain antibody is constructed, then the CAR is transcribed to obtain mRNA, LNP entrapped with mRNA is prepared, then the CD7 antibody subjected to amino acid sequence optimization is adopted to be coupled with the LNP entrapped with mRNA, the transfection efficiency of the CD7 antibody in T cells is high, the CD7 antibody is injected into a mouse tumor model, and the lifetime of mice can be prolonged; t cells transfected by the T cell transfecting agent have high killing efficiency on HELA cells and LOVO cells.

Provided are a liver precursor cell and a construction method therefor and the use thereof. The method for constructing liver precursor cells comprises the steps of: S0, providing liver precursor cells, a mixed solution and a reprogramming culture medium, wherein the mixed solution comprises a serum-free culture medium, polyethyleneimine and a CLP plasmid; S1, carrying out a transfection treatment on the liver precursor cells and the mixed solution to obtain transfected liver precursor cells; and S2, placing the transfected liver precursor cells into the reprogramming culture medium for subculture to obtain immortalized liver precursor cells. The method solves the problems that in the prior art, liver precursor cells cannot be transformed into immortalized cell strains by means of immortalizing genes and cannot be continuously passaged in vitro.

The invention belongs to the technical field of biological medicine, and particularly relates to an engineered cell microvesicle and a delivery system based on the engineered cell microvesicle, the system realizes efficient preparation of 1-5 [mu] m cell microvesicles, and the cell microvesicles have a large space volume and can be used for preparing the cell microvesicles. The carrier can be used for loading and delivery of target protein, polypeptide and recombinase which are specifically expressed in mother cells. The system transfects mother cells through lentivirus transfection or plasmid transfection to further produce cell microvesicles, and the microvesicles can load more goods and inherit membrane proteins of the mother cells, and can also effectively load intracellular proteins to realize effective delivery. By virtue of good structural stability, high immunogenicity and excellent biocompatibility, the cell microvesicle reduces systematic toxic and side effects of a traditional carrier, is expected to become an effective drug delivery system, and has great application potential in the field of gene therapy.

The invention relates to a preparation method of a binary guanidyl block copolymer (Poly-PEG-GUA) for nucleic acid transfection of human vascular endothelial cells (HUVEC). According to the invention, N-(2-(3-carbamyl guanidyl) ethyl) methacrylamide with different proportions is subjected to reversible addition-fragmentation chain transfer (RAFT) polymerization to polyethylene glycol modified 4-cyano-4-(phenyl thioformyl sulfenyl) valeric acid (PEG-CPADN), so that five kinds of binary guanidyl block copolymers with different molecular weights are constructed; the HUVEC gene and messenger ribonucleotide (EGFP-mRNA) of green fluorescent protein are assembled in the HUVEC for screening of transfection efficiency, and the optimal molecular weight for HUVEC transfection is optimized. Experimental results show that the Poly-PEG-GUA with the molecular weight of 53575 Daltons can be used for effectively delivering green fluorescent protein (EGFP) mRNA (messenger ribonucleic acid) to HUVEC (human umbilical vein endothelial cells), and the highest transfection efficiency is shown. The optimized Poly-PEG-GUA in the invention has a certain reference value for the research and development of subsequent cardiovascular transfection products.

The invention provides a stem cell exosome for overexpressing A beta degrading enzyme as well as a preparation method and application of the stem cell exosome. Specifically, the invention provides an application of the stem cell exosome overexpressing A beta degrading enzyme in preparation of drugs, and the drugs are used for at least one of the following: prevention, improvement or treatment of cognitive impairment related diseases; neuronal cell damage is improved; wherein the stem cells for overexpressing the A beta degrading enzyme are prepared through lentivirus transfection. According to the stem cell exosome overexpressing the A beta degrading enzyme, the content of the A beta degrading enzyme is obviously higher than that of the exosome prepared by a traditional method. Therefore, when the compound is prepared into a medicine for treating or preventing cognitive impairment related diseases, the medicine can be efficiently conveyed to the brain, and the concentration of the medicine in the brain is remarkably improved, so that the curative effect is enhanced, the dosage of the medicine can be reduced, the side effect is reduced, and the prognosis of brain diseases is effectively improved.

The present invention belongs to the field of drug delivery. Provided is an asymmetric cationic lipid containing a branched piperazine ring and having a structure as shown in general formula (1), wherein the definition of each symbol is consistent with that described in the text. In the cationic lipid of the present invention, a degradable group is introduced at an appropriate position, and the presence of the degradable group makes an LNP-pharmaceutical composition prepared therefrom be degraded at an appropriate time in vivo and have a low cytotoxicity, which solves the problems in the prior art that an LNP-pharmaceutical composition prepared from a non-degradable lipid can accumulate in endosomes and acidify the endosomal environment, so that the endosomal escape of a drug (e.g., mRNA) is hindered, and the drug delivered into cells cannot fully function. In the cationic lipid of the present invention, a heterofunctionalized small molecule containing a piperazine ring is used as a raw material. The preparation process is simple and convenient, has a lower cost, and is more environmentally friendly. The LNP-mRNA composition prepared therefrom has the advantages of low toxicity, high biocompatibility, high cell transfection, etc.